Pentedrone
α-propyl-N-methylcathinone
Viewing r1 — Apr 26, 2026
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Pentedrone (2-(methylamino)-1-phenylpentan-1-one) — "bath salts" — is a synthetic stimulant of the cathinone class. It sits between α-PVP and mephedrone in potency, resembling cocaine in character rather than empathogenic cathinones. It blocks the clearance of dopamine and norepinephrine from the brain,[1] producing focused stimulation and motivational drive.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, amphetamine, methamphetamine +2 morecocaine, amphetamine, methamphetamine, methylphenidate, other synthetic cathinones show less
Pentedrone appeared on illicit markets in 2010 as a "bath salt" replacement following the UK ban on mephedrone.[2] Vendors openly marketed it as an unscheduled substitute for controlled cathinones, and by 2013 it ranked among Europe's most-seized novel stimulants. It is now controlled under UN Psychotropic Schedule II and Schedule I in the United States.[3]
Subjective effects include stimulation, motivation enhancement, cognitive euphoria, mental focus, and appetite suppression.[4] The experience is narrow and task-oriented — dopaminergic drive without the emotional warmth of serotonin-active compounds, closer in character to cocaine than to mephedrone. Anxious overstimulation, compulsive redosing, and a flat, depleted comedown are characteristic unwanted effects.
Dependence liability is substantial — pentedrone drives compulsive patterns in animals[5] and depletes dopamine with repeated use; in vitro liver toxicity exceeds that of MDMA.[6] The short peak drives compulsive redosing that compounds cardiovascular strain — the primary acute danger[7] — and combining it with MAOIs or other stimulants dramatically amplifies risk. No controlled human studies exist — the current understanding rests on cell studies, animal models, forensic cases, and analogy to related compounds.
History[edit]
History
Discovery
Pentedrone appeared on illicit markets in 2010, sold as a "bath salt" in the US and UK, emerging in the wave of synthetic cathinones that followed the UK ban on mephedrone in April 2010.[2] Its first formal chemical identification was published by Maheux and Copeland in 2012.[8]
Market evolution
After the DEA emergency-scheduled three cathinones in 2011, at least one vendor reformulated its products to contain pentedrone as the unscheduled replacement.[9] By 2013, approximately 197 kg had been seized across Europe, placing it among the most-intercepted synthetic cathinones alongside α-PVP and 3-MMC.[10]
Prohibition and modern status
The US placed pentedrone in emergency Schedule I in 2014,[11] extended in 2016,[12] and permanently scheduled it in 2017.[3] Following a 2016 WHO review, it entered UN Psychotropic Schedule II.[13] Wastewater and forensic studies confirm ongoing use across Europe into the late 2010s.[14][15][16]
The name "pentedrone" reflects its five-carbon backbone ("pent-") and cathinone lineage ("-edrone"). It circulated under branded bath salt products — most notably "Raving Dragon Voodoo Dust," explicitly marketed as a replacement for the recently scheduled methylone.[9]
Chemistry[edit]
Chemistry
Structural class
Pentedrone belongs to the synthetic cathinone family — β-keto phenethylamines derived from cathinone, the principal alkaloid of the khat plant (Catha edulis). Its five-carbon backbone ("pent-") distinguishes it from shorter analogues like methcathinone and buphedrone, and from longer-chain compounds like hexedrone.
Molecular properties
| Molecular formula | C₁₂H₁₇NO |
| Molecular weight | 191.27 g/mol |
The molecule features an unsubstituted phenyl ring, a β-carbonyl group, an N-methylamino substituent, and a propyl side chain.[17]
Pharmacology[edit]
Pharmacology
Mechanism of action
Pentedrone blocks the reuptake of dopamine and norepinephrine without triggering their release[1] — a mechanism resembling cocaine rather than amphetamine. It has minimal serotonin activity,[5] which explains the absence of emotional warmth or empathic effects. The consensus is a purely dopamine- and norepinephrine-selective blocking profile,[10] though one study identified a possible hybrid releasing component.[18]
Pharmacokinetics
No controlled human pharmacokinetic data exist for pentedrone. The closest human evidence comes from N-ethylpentedrone: at 30 mg intranasally, concentrations peaked within an hour and effects returned to baseline within 3–4 hours.[19][20] A severe intoxication case found blood concentrations still elevated after 17 hours of monitoring,[7] suggesting a prolonged half-life.
Pentedrone is broken down mainly through carbonyl reduction; unchanged drug is largely absent from urine. A reduced alcohol metabolite serves as the primary marker of use,[21] and this metabolite is shared with α-PVP and N-ethylpentedrone, complicating forensic identification.[22]
Neuroscience[edit]
Neuroscience
Where it acts
Pentedrone's action concentrates in the brain's reward circuit — the pathway from the midbrain to the nucleus accumbens — and in the prefrontal cortex.[1] Dopamine buildup there produces euphoria and reinforcement; norepinephrine drives arousal and alertness. The result is focused stimulation with motivational drive, without the emotional openness produced by serotonin-active compounds.
Addiction and neuroplasticity
Pentedrone produces conditioned place preference in mice, directly demonstrating its rewarding properties.[5] Repeated exposure to the related N-ethylpentedrone builds a molecular marker in the striatum associated with the shift from casual to compulsive use, alongside striatal dopamine depletion and withdrawal effects including aggression and impaired social behavior.[23] Class-level evidence links synthetic cathinones to neuroinflammation and transporter damage with repeated use.[24]
Whether the two enantiomers differ in abuse potential in humans is unknown — cell data suggests they do,[25] but no human studies exist. Whether the striatal dopamine depletion seen in animal models[23] translates to lasting impairment in human users remains unanswered. No neuroimaging studies have been conducted.
Subjective Effects[edit]
Pentedrone produces a narrow, task-oriented stimulant experience — mentally sharp, motivated, and alert, with a pronounced drive toward focused activity. There is no warmth, no empathic opening, no euphoric haze. At higher doses, the focus tips into restless hypervigilance and anxious agitation.
The closest comparison is cocaine — both block dopamine reuptake and produce a focused rush without serotonergic warmth.[4] Pentedrone differs in a longer aftereffect tail and more pronounced residual dysphoria after the peak subsides. Methylphenidate offers a secondary anchor — same mechanism, but slower and less abrupt.
Effect Grid
At common doses, pentedrone's full stimulant profile manifests: pronounced cognitive euphoria, strong motivation enhancement, thought acceleration, and marked wakefulness. Focus intensification can produce a driven, task-oriented state. Appetite suppression is strong. Entactogenic effects are notably absent — the experience is primarily dopaminergic rather than serotonergic.
Cardiovascular effects become significant: elevated heart rate, increased blood pressure, and vasoconstriction. Jaw tension (bruxism), sweating, and mydriasis are typical. Body temperature rises modestly. The compulsive redosing urge is prominent at this range due to the short peak duration.
Sleep is impossible for 2–4 hours after the last dose. Aftereffects include residual stimulation, irritability, and potential low mood as dopaminergic effects wane.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Touch enhancement · Tinnitus · Auditory hallucinations · External hallucinations · Shadow people
External hallucinations · Shadow people
Pupil dilation · Dehydration sensation · Dry mouth · Insomnia · Physical fatigue · Restlessness · Excessive sweating · Bruxism · Spontaneous body sensations · Body high · Heart rate perception changes · Muscle tension · Respiratory stimulation · Dizziness · Headache · Nausea · Tingling / electric sensations · Trembling · Vibrations / buzzing · Sexual arousal suppression · Tactile euphoria · Constipation · Involuntary body movements · Motor control impairment · Sexual arousal enhancement · Vomiting · Tactile hallucination
Insomnia · Physical fatigue · Restlessness · Excessive sweating · Bruxism · Spontaneous body sensations · Body high · Heart rate perception changes · Muscle tension · Respiratory stimulation · Dizziness · Headache · Nausea · Tingling / electric sensations · Trembling · Vibrations / buzzing · Sexual arousal suppression · Tactile euphoria · Constipation · Involuntary body movements · Sexual arousal enhancement · Vomiting · Tactile hallucination
Motivation suppression · Focus enhancement · Motivation enhancement · Information processing enhancement · Analysis enhancement · Thought deceleration · Immersion enhancement · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Conceptual thinking · Focus suppression · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Confusion · Thought loops · Cognitive impairment · Thought disorganization · Delirium · Delusions
Information processing enhancement · Analysis enhancement · Thought deceleration · Immersion enhancement · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Conceptual thinking · Focus suppression · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Creativity enhancement · Humor enhancement · Language enhancement · Thought organization · Confusion · Thought loops · Cognitive impairment · Thought disorganization · Delusions
Anxiety · Dysphoria · Emotional enhancement · Emotional lability · Mania
Emotional lability
Sociability enhancement · Social connection · Communication enhancement · Flow state · Automaticity
Automaticity
Timeline
First alerts emerge as mild restlessness and a subtle lift in mood. Physical sensations are minimal — a faint increase in heart rate may be noticeable.
Stimulation builds steadily with increasing alertness, thought acceleration, and rising heart rate. Appetite suppression begins. Mild jaw tension may appear.
Full stimulant effects: pronounced cognitive euphoria, strong motivation enhancement, wakefulness, and appetite suppression. Cardiovascular effects (tachycardia, hypertension) are at their maximum. Compulsive redosing urge is strongest during this phase.
Stimulation gradually recedes. Euphoria fades first, leaving residual wakefulness and mild irritability. Cardiovascular parameters begin normalizing.
Residual effects include lingering wakefulness, mild dysphoria or flatness, and possible difficulty sleeping. Irritability and low mood may persist as dopaminergic tone recovers.
⚠ Do not drive or operate machinery until sleep has been obtained and residual stimulation has fully resolved.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- cocaine · amphetamine · methamphetamine
Toxicity
No lethal dose has been established for pentedrone in humans or animals. All safety data comes from cell studies, animal experiments, forensic casework, and case reports involving related compounds.
Liver toxicity
In vitro testing shows pentedrone is significantly more toxic to liver cells than MDMA, causing oxidative stress, energy depletion, and cell death.[6] The significance for chronic human use is unknown, but the findings raise concern for liver injury in heavy or repeated use.
Neurotoxicity
In cell studies, the S-(+) form of pentedrone causes greater oxidative damage and death in dopamine neurons than the R-(-) form.[25] Cathinones in this class show greater neurotoxicity than methamphetamine in cell models, with toxicity increasing as the side chain lengthens.[26]
Overheating
Dangerous overheating is a major class-level risk for synthetic cathinones, with severe cases documented in clinical literature.[27] N-ethylpentedrone produced body temperature increases in animal studies during repeated dosing.[23]
Severe intoxication
No confirmed pentedrone-only fatality appears in the peer-reviewed literature. An unverified report describes a death from pentedrone combined with α-PVP causing heart failure,[13]safety citation needed and a fatal case involving 4-methylpentedrone (a ring-substituted derivative) occurred in a chemsex context with multiple other substances present.[28]
The most informative case involves N-ethylpentedrone: a man who snorted the substance developed blood concentrations exceeding 2,000 ng/mL with severe agitation, paranoid delusions, rapid heart rate, fever, muscle breakdown, kidney failure, and coma requiring 3 days in intensive care.[7] Treating physicians noted he "would most likely have died without intensive care."
Expected toxidrome
Based on cathinone class literature and the N-ethylpentedrone case,[7] the expected pattern of toxicity includes:
- Cardiovascular: rapid heart rate, high blood pressure
- Neurological/psychiatric: agitation, paranoia, hallucinations, seizure risk
- Metabolic: muscle breakdown, kidney failure (severe cases)
- Thermoregulatory: dangerous overheating
- Ophthalmological: dilated pupils
No specific antidote exists. Treatment is supportive: benzodiazepines for agitation, active cooling for overheating, aggressive fluids for muscle breakdown, and intensive care for severe presentations.[29]
Seek immediate medical attention for: loss of consciousness, chest pain, severe agitation or psychosis, fever exceeding 38.5°C, or seizures. Clinical deterioration can occur rapidly — an initially stable presentation may progress to organ failure within hours.[7]
Psychological risks
Acute adverse effects include anxiety, agitation, irritability, paranoid thinking at higher doses, and insomnia.[30] The short duration and compulsive redosing cycle amplify psychological distress through sleep deprivation and dopamine depletion. No data exist on long-term psychiatric effects specific to pentedrone.
Tolerance and dependence
Tolerance develops through DAT downregulation and dopamine depletion. Class-level estimates suggest tolerance halves in approximately 5 days and fully resets at approximately 1.5 weeks. inferred Cross-tolerance with cocaine, amphetamines, and other cathinones is expected.
Dependence liability is substantial. Pentedrone produces conditioned place preference in mice.[5] The closely related N-ethylpentedrone produces robust accumulation of a molecular addiction marker in the striatum, alongside withdrawal effects including aggression, impaired social behavior, elevated stress hormones, and striatal dopamine depletion.[23]
Drug interactions
Noradrenergic potentiation
Combining pentedrone with other norepinephrine-active drugs risks dangerous blood pressure spikes, rapid heart rate, and cardiovascular collapse. Tramadol is of particular concern: as both an opioid and a norepinephrine reuptake inhibitor, it adds to norepinephrine load while lowering the seizure threshold through two separate mechanisms. safety citation needed
Serotonergic combinations
Combining with MDMA adds cardiovascular strain, with particular risk in warm environments or during physical activity. If pentedrone has any serotonin-releasing activity,[18] MDMA-induced serotonin flooding could trigger dangerous overheating and seizures — a potentially life-threatening response. Combining with MAOIs carries severe risk through impaired catecholamine breakdown.
Stimulant stacking
Combining with other stimulants — cocaine, amphetamines, other cathinones — produces additive cardiovascular strain and overheating risk. Pentedrone has been found in syringe residues from chemsex sessions alongside multiple other substances.[31]
Alcohol
No specific interaction data exist. The standard stimulant-alcohol pattern applies: the stimulant masks sedation, leading to excess consumption of both, compounded by cardiovascular strain.
Detection
Pentedrone does not trigger positive results on standard amphetamine drug tests.[32] Confirmation requires specialized laboratory testing. This evasion of routine screening has important implications for emergency treatment and monitoring programs.
Contraindications
Heart conditions — high blood pressure, coronary artery disease, irregular heartbeat, structural heart disease — carry the highest risk under additional stimulant load. Liver impairment elevates risk given pentedrone's in vitro liver toxicity exceeding MDMA.[6]
Psychotic disorders, bipolar disorder, and seizure disorders are relative contraindications, as dopamine stimulation may trigger or worsen psychosis, mania, or seizures. Pregnancy and breastfeeding are absolute contraindications. Concurrent MAOI use is absolutely contraindicated due to the risk of dangerous blood pressure crisis.
Harm Reduction[edit]
Harm reduction
Forms & Identification
Pentedrone appears as a white crystalline powder, visually indistinguishable from other synthetic cathinones. Standard immunoassay drug panels do not detect it[32] — a negative result provides no safety assurance. Reagent testing can confirm cathinone class membership, but even specialized labs struggle to distinguish pentedrone from its eight positional isomers.[33]
Set & Setting
The serotonin-absent profile makes pentedrone's character heavily dependent on context. In a calm, task-oriented setting, the stimulation tends toward productive focus; in a chaotic or overheated environment, the same pharmacology produces anxious hypervigilance and paranoid thinking.
The short peak and abrupt offset create strong compulsive redosing urges. Establishing a firm session plan before the first dose is one of the most effective harm reduction measures for this compound class.
Guidelines
- Test every batch. Reagent testing confirms the cathinone class; quantitative analysis (if accessible) addresses purity and identity.
- Set a firm dose and stick to it. Measure with a milligram-precision scale. Eyeballing powder doses is unreliable and dangerous.
- Remove redose material from the environment before taking the first dose. The compulsive redosing drive is pharmacologically inherent, not a willpower failure.
- Stay hydrated but do not overhydrate — aim for regular sips of water rather than large volumes.
- Avoid hot environments and extended physical activity. Overheating is a serious cathinone class risk.
- Set a curfew. Sleep deprivation amplifies anxiety, paranoia, and perceptual disturbances with each missed sleep cycle.
- Have a trusted person aware of what was taken, when, and how much.
- Eat before dosing. Appetite suppression is pronounced; pre-loading nutrition reduces post-session depletion.
Aftercare & Integration
The stimulant comedown from pentedrone reflects acute dopamine depletion and sleep disruption. Sleep is the single most restorative intervention — a full sleep cycle takes priority above all else. Eat nutrient-dense meals even if appetite is absent; appetite suppression outlasts the stimulant effects.
Avoid redosing to manage the comedown. The dysphoria, fatigue, and low motivation following use are time-limited neurochemical effects, not a permanent state. If depression, anxiety, or cravings persist beyond 72 hours, consider professional consultation.
Recovery & Support
Pentedrone's compulsive redosing pattern and dopamine-depleting profile can escalate into dependent use, particularly during binge sessions. If use has become difficult to control, or if sessions are extending beyond planned limits, this signals a pattern that benefits from external support.
SMART Recovery and stimulant-specific support groups address the cognitive and behavioral patterns characteristic of cathinone dependence. A healthcare provider experienced with stimulant use disorders can assess whether pharmacological or therapeutic support is appropriate. Harm reduction services in many regions offer confidential, non-judgmental guidance — seeking help is not contingent on committing to abstinence.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable stimulant effects — jitteriness, mild anxiety, rapid heartbeat — are distinct from medical emergencies. Seek immediate help for: chest pain, seizure, loss of consciousness, body temperature hot to the touch through clothing, severe paranoid psychosis (loss of contact with reality), or uncontrollable agitation.
Immediate steps:
- 1. Call emergency services.
- 2. Move the person to a cool, quiet environment.
- 3. If unconscious but breathing, place in the recovery position.
- 4. Do not restrain unless immediate danger of self-harm — restraint worsens overheating and agitation.
- 5. Remove excess clothing and apply cool (not ice-cold) water if overheating is suspected.
- 6. Stay with the person until help arrives.
What to tell the dispatcher: Name the substance (synthetic cathinone / pentedrone), estimated amount and time of use, current symptoms, and whether other substances were taken. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Clinical deterioration can be rapid — initial presentation may appear non-critical before progressing to organ failure within hours.[7]
Legal Status[edit]
Legal status
Pentedrone is internationally controlled. Following a 2016 WHO Expert Committee review, it was placed in UN Psychotropic Schedule II,[13][34] and holds Schedule I status in the United States and Class B in the United Kingdom.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary emergency Schedule I from 27 February 2014;[11] extended 2016;[12] permanently placed March 2017[3] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under generic cathinone amendment effective 16 April 2010[2] |
| Germany | Anlage II (authorized trade only) | Specific scheduling date not confirmed from primary sourcescitation needed |
| China | Controlled substance | Scheduled October 2015[13] |
| Australia | Controlled substance | Listed in ODC database; specific scheduling date not confirmedcitation needed |
| Canada | Controlled substance | Confirmed controlled; specific scheduling date not confirmedcitation needed |
| Brazil | F2 | Controlled; specific provision not confirmed[13] |
| Czech Republic | Banned | Specific provision not confirmed[13] |
| United Nations | Psychotropic Schedule II | Following WHO ECDD 38th meeting recommendation (2016)[13] |
Legal status changes frequently and varies by jurisdiction. This table reflects information available at time of publication and is not legal advice.
references
- [1] ^abcSimmler LD, Rickli A, Hoener MC, Liechti ME (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones — Neuropharmacology doi:10.1016/j.neuropharm.2013.11.008
- [2]
- [3] ^abcDrug Enforcement Administration (2017) Schedules of Controlled Substances: Placement of 10 Synthetic Cathinones Into Schedule I. Final rule. — Federal Register PMID:28355044
- [4] ^abDrevin G, Gaulier JM, Hakim F, et al. (2024) Synthetic cathinones in drug-facilitated sexual assault: A case report involving N-ethylpentedrone — Forensic science international doi:10.1016/j.forsciint.2024.112030
- [5] ^abcdDuart-Castells L, Nadal-Gratacós N, Muralter M, Puster B, Berzosa X, Estrada-Tejedor R, Niello M, Bhat S, Pubill D, Camarasa J, Sitte HH, Escubedo E, López-Arnau R (2021) Role of amino terminal substitutions in the pharmacological, rewarding and psychostimulant profiles of novel synthetic cathinones. — Neuropharmacology doi:10.1016/j.neuropharm.2021.108475
- [6] ^abcValente MJ, Araújo AM, Bastos Mde L, Fernandes E, Carvalho F, Guedes de Pinho P, Carvalho M (2016) Characterization of Hepatotoxicity Mechanisms Triggered by Designer Cathinone Drugs — Toxicological sciences doi:10.1093/toxsci/kfw105